Investigating the Effect and Potential Mechanism of Rhamnetin 3--α-Rhamnoside on Acute Liver Injury In Vivo and In Vitro.

: Rhamnetin 3--α-rhamnoside (ARR) is a major flavonoid of the herb Franch. & Sav., which has been used for treating liver diseases in China.

Reduced Glutathione Promoted Growth Performance by Improving the Jejunal Barrier, Antioxidant Function, and Altering Proteomics of Weaned Piglets.

Reduced glutathione (GSH) is a main nonenzymatic antioxidant, but its effects and underlying mechanisms on growth and intestinal health in weaned piglets still require further assessment. A total of 180 weaned piglets were randomly allotted to 5 groups: a basal diet (CON), and a basal diet supplemented with antibiotic chlortetracycline (ABX), 50 (GSH1), 65 (GSH2), or 100 mg/kg GSH (GSH3). Results revealed that dietary GSH1, GSH2, and ABX improved body weight and the average daily gain of weaned piglets, and ABX decreased albumin content but increased aspartate aminotransferase (AST) activity and the ratio of AST to alanine transaminase levels in plasma.

A nucleocapsid monoclonal antibody based sandwich ELISA for the general detection of both PRRSV-2 and PRRSV-1.

Porcine reproductive and respiratory syndrome virus (PRRSV) causes reproductive failure in sows and respiratory disease in growing pigs, leading to significant economic losses worldwide. Due to the constant mutation and recombination, PRRSV exhibits significant genetic diversity, the general detection of all PRRSV-2 and PRRSV-1 strains is thus needed. In our study, four monoclonal antibodies (mAbs) against PRRSV nucleocapsid (N) protein were generated and the precise and novel B cell epitopes (KPHF and HHTVR) were identified.

Sustainable performance evaluation of pharmaceutical companies: sustainable balanced scorecard and hybrid MCDM approach.

Despite the increasing demand for sustainable development of pharmaceutical companies due to the rigorous pressure of environmental regulation, public health crisis and economic competition, there has been little research on relevant evaluation models. The COVID-19 experience has also prompted investors in pharmaceutical companies to re-examine the impact of environment and ethics on business development. Therefore, pharmaceutical companies need to focus on their performance, especially on the shift from a single financial performance to an integrated performance.

Improving estimation efficiency for survival data analysis by integrating a coarsened time-to-event outcome from an external study.

In the era of big data, increasing availability of data makes combining different data sources to obtain more accurate estimations a popular topic. However, the development of data integration is often hindered by the heterogeneity in data forms across studies. In this paper, we focus on a case in survival analysis where we have primary study data with a continuous time-to-event outcome and complete covariate measurements, while the data from an external study contain an outcome observed at regular intervals, and only a subset of covariates is measured.